A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03).

MLA

Procopio, Giuseppe, et al. “A Multicenter Phase 2 Single Arm Study of Cabozantinib in Patients with Advanced or Unresectable Renal Cell Carcinoma Pre-Treated with One Immune-Checkpoint Inhibitor: The BREAKPOINT Trial (Meet-Uro Trial 03).” Tumori, vol. 109, no. 1, Feb. 2023, pp. 129–37. EBSCOhost, https://doi.org/10.1177/03008916221138881.

APA

Procopio, G., Claps, M., Pircher, C., Porcu, L., Sepe, P., Guadalupi, V., De Giorgi, U., Bimbatti, D., Nolè, F., Carrozza, F., Buti, S., Iacovelli, R., Ciccarese, C., Masini, C., Baldessari, C., Doni, L., Cusmai, A., Gernone, A., Scagliarini, S., … Verzoni, E. (2023). A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03). Tumori, 109(1), 129–137. https://doi.org/10.1177/03008916221138881

Chicago

Procopio, Giuseppe, Mélanie Claps, Chiara Pircher, Luca Porcu, Pierangela Sepe, Valentina Guadalupi, Ugo De Giorgi, et al. 2023. “A Multicenter Phase 2 Single Arm Study of Cabozantinib in Patients with Advanced or Unresectable Renal Cell Carcinoma Pre-Treated with One Immune-Checkpoint Inhibitor: The BREAKPOINT Trial (Meet-Uro Trial 03).” Tumori 109 (1): 129–37. doi:10.1177/03008916221138881.